FLT3

ESH 2019 | How will the use of FLT3 inhibitors evolve in the future?

L:

The AML Global Portal were delighted to speak to Catherine Smith, UCSF Medical Center, San Francisco, US , during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Catherine Smith: How will the use of FLT3 inhibitors evolve in the future?

She provided her expert opinion outlining the challenge of resistance development, both on-target and off-target and how the field is currently trying to overcome them with drug combination regimens. She provided arguments for a sequential use of different treatment modalities in order to better address the heterogeneity of AML at diagnosis and relapse.

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!
100% of people found this article informative